For research use only. Not for therapeutic Use.
MSDC-0602 (Cat.No:I008173) is a compound under investigation for its potential therapeutic applications. It belongs to a class of drugs known as mitochondrial-targeted compounds, which are designed to improve mitochondrial function and restore cellular energy balance. MSDC-0602 shows promise in preclinical studies for the treatment of various metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH). Further research is underway to evaluate its safety and effectiveness in human trials.
| Catalog Number | I008173 |
| CAS Number | 1133819-87-0 |
| Synonyms | MSDC-0602; MSDC0602; MSDC 0602;5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione |
| Molecular Formula | C19H17NO5S |
| Purity | ≥95% |
| Target | Vitamin D Related/Nuclear Receptor |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| IUPAC Name | 5-[[4-[2-(3-methoxyphenyl)-2-oxoethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
| InChI | InChI=1S/C19H17NO5S/c1-24-15-4-2-3-13(10-15)16(21)11-25-14-7-5-12(6-8-14)9-17-18(22)20-19(23)26-17/h2-8,10,17H,9,11H2,1H3,(H,20,22,23) |
| InChIKey | YAUMOGALQJYOJQ-UHFFFAOYSA-N |
| SMILES | COC1=CC=CC(=C1)C(=O)COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3 |
| Reference | </br>1:McCommis KS, Hodges WT, Brunt EM, Nalbantoglu I, McDonald WG, Holley C, Fujiwara H, Schaffer JE, Colca JR, Finck BN. Targeting the Mitochondrial Pyruvate Carrier Attenuates Fibrosis in a Mouse Model of Nonalcoholic Steatohepatitis. Hepatology. 2016 Dec 27. doi: 10.1002/hep.29025. [Epub ahead of print] PubMed PMID: 28027586.</br>2:Fukunaga T, Zou W, Rohatgi N, Colca JR, Teitelbaum SL. An insulin-sensitizing thiazolidinedione, which minimally activates PPARγ, does not cause bone loss. J Bone Miner Res. 2015 Mar;30(3):481-8. doi: 10.1002/jbmr.2364. PubMed PMID: 25257948; PubMed Central PMCID: PMC4472363. |
